$7.49
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

DarioHealth Corp. is a digital health company which offers a user-centric and multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company is headquartered in New York City, New York and currently employs 160 full-time employees. The company went IPO on 2013-03-08. The Company’s platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. Its digital therapeutic platform has been designed with a user-first strategy, focusing on the user’s needs and user experience and satisfaction. Dario Blood Glucose Monitoring Starter Kit is a pocket-sized smartphone glucometer that manages diabetes in one ultra-compact device. Dario Blood Pressure Monitoring System is a blood pressure monitoring system used to measure blood pressure, which allows it to store all its user readings in the Dario App. The Dario mobile app is a complete, cloud-based solution for personal chronic condition management.
Country

US

CEO

Mr. Erez Raphael

IPO date

2013

Employees

160

ISIN

US23725P3082

Key stats

Open

$7.25

Volume

4.84K

Market cap

$73.40M

Prev. close

$7.49

Impl / hst vl

-

Open interest

$0.00

$7.10

Day’s Range

$8.06

$5.84

52W Range

$13.65

Valuation

22
Valuation score
Overvalued
P/E
-
P/S
3.51
P/B
1.19
Current ratio
-
Debt / Equity
0.50
ROE
-
Gross margin
-
Income growth
-3.94%
FCF growth
1.07

Analysts estimates

Consensus rating
Buy

The average rating from top 5 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$15.56
The top 6 analysts forecasts that 12-month price may increase by 107.68%, with a low of $10.10 and a high of $29.40
$10.10
Low
$15.56
Avg
$29.40
High
Current price

Earnings

Q2 ‘26 revenue
$5.18M
Q2 ‘26 net income
-$7.92M
Revenue
Net income
Previous EPS
-$1.25
Estimate EPS
-$1.24
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply